Tonix Pharmaceuticals Highlights TONMYA’s Efficacy in Fibromyalgia Treatment at AAPM Meeting
Event summary
- Tonix Pharmaceuticals presented data on TONMYA at the 2026 AAPM PainConnect Annual Meeting, showing statistically significant pain reduction in two Phase 3 trials.
- TONMYA was commercially launched in November 2025 and is the first new FDA-approved treatment for fibromyalgia in over 15 years.
- The RESILIENT trial involved 457 patients and demonstrated clinically meaningful improvements in patient-centered outcomes.
- TONMYA’s unique sublingual formulation reduces the formation of norcyclobenzaprine, addressing limitations of oral cyclobenzaprine.
The big picture
Tonix Pharmaceuticals is positioning TONMYA as a safer, more effective alternative to existing fibromyalgia treatments. The drug’s unique formulation and FDA approval address significant unmet medical needs in a chronic condition affecting millions of adults in the U.S. The company’s focus on expanding its CNS portfolio could further solidify its market presence.
What we're watching
- Market Adoption
- Whether TONMYA can gain significant market share against existing fibromyalgia treatments with higher discontinuation rates.
- Pipeline Expansion
- The pace at which Tonix advances TONMYA for other indications like major depressive disorder and acute stress disorder.
- Patent Protection
- How long Tonix can maintain exclusivity in the fibromyalgia market given its patents extend until 2034/2035.
Our editorial coverage:
Related topics